Aquatic Capital Management LLC Has $4.96 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

Aquatic Capital Management LLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 225.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 113,405 shares of the company’s stock after acquiring an additional 78,605 shares during the quarter. Aquatic Capital Management LLC’s holdings in Revolution Medicines were worth $4,960,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RVMD. Oxford Asset Management LLP bought a new stake in shares of Revolution Medicines during the 4th quarter valued at $730,000. Susquehanna Fundamental Investments LLC bought a new stake in Revolution Medicines in the fourth quarter valued at about $9,995,000. Ghisallo Capital Management LLC bought a new stake in Revolution Medicines in the fourth quarter valued at about $11,246,000. Lord Abbett & CO. LLC lifted its stake in Revolution Medicines by 8.0% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,978,720 shares of the company’s stock valued at $86,549,000 after buying an additional 146,699 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in Revolution Medicines by 1.2% during the fourth quarter. Voya Investment Management LLC now owns 316,028 shares of the company’s stock worth $13,823,000 after buying an additional 3,901 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the transaction, the chief financial officer now directly owns 115,006 shares in the company, valued at $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Margaret A. Horn sold 3,058 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,660 shares of company stock worth $650,406. Insiders own 8.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on RVMD shares. UBS Group increased their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Stifel Nicolaus cut their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and issued a $59.00 price target on shares of Revolution Medicines in a report on Tuesday, April 8th. Wedbush reaffirmed an “outperform” rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. Finally, HC Wainwright boosted their target price on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average target price of $66.67.

Revolution Medicines Price Performance

RVMD stock opened at $38.77 on Friday. The stock has a market capitalization of $7.21 billion, a P/E ratio of -10.80 and a beta of 1.37. The business has a 50-day moving average of $37.43 and a 200-day moving average of $44.05. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). Equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.